Abstract:
The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
Abstract:
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.
Abstract:
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.
Abstract:
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
Abstract:
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
Abstract:
Techniques are described for optimizing processing facilities of a receiver in a wireless communication environment, taking into consideration processing performance set against the computing resources and/or power consumption required to obtain the processing performance. An embodiment of a radio receiver is described that includes a channel equalization means arranged to receive digital samples of an incoming signal and to generate an equalized output, said channel equalization means including means for processing said digital samples in accordance with an equalizer algorithm utilizing a set of equalizer parameters. The receiver can include means for estimating at least one parameter of a channel over which the signal has been received, and means for selecting at least one of said equalizer parameters based on at least one of said estimated channel parameters. Related methods, algorithms, and computer program products are also described.
Abstract:
A belt (10) for an electrokinetic belt press (100) comprises a woven material, and having an electrical transfer zone (18) extending longitudinally along the belt (10) between a filtration zone (12) and an edge (22) of the belt (10), the electrical transfer zone (18) comprising a plurality of electrically-conducting warp elements arranged as a plurality of substantially parallel stripes (26), wherein adjacent stripes (26) are separated from each other in the transverse direction by at least one electrically-insulating warp element (28). The stripes (26) may be discontinuous in order to electrically isolate discrete conducting zones (14) of the filtration zone (14), the discontinuities being displaced longitudinally from each other. Also, an electrokinetic belt press apparatus (100) is described, comprising a pair of filtration belts (110, 111), at least one of which comprises a plurality of discrete conducting areas (14). A plurality of independent power supplies (P1-P6) are connected between contact elements (120, 121) for contacting the filtration belts (110, 111). The apparatus (100) further includes means (240, 250, 251) for applying a reverse polarity to one of the belts to de-cake the belt, and means (260, 270, 280, 290) for recirculating filtrate from the distal end (190) of a dewatering section (170) of the apparatus to the proximal end (180).
Abstract:
An apparatus and method for reducing the liquid content of a particulate/liquid dispersion, such as a sewage sludge or mine tailings, are described. The apparatus comprises containment means to contain the material, and means to apply pressure to the contained material therein, the containment means being partly defined by a first filtration membrane permeable to the liquid but impermeable to at least some and more preferably substantially all of the solids contained within the material, in particular configured as a continuous belt press. The filtration membrane comprises a textile or other synthetic material in intimate association with a conducting element so as to constitute where so associated a first electrode. A second sheet material, preferably also a filtration membrane, is similarly associated with a conducting element so as to constitute a second electrode to allow application of a potential difference across the material and drive the dewatering process electrokinetically. Preferably, the apparatus is a belt filter press, and includes means to apply a variable and intermittent voltage to, and insulate from each other, two electrodes configured a continuously moving belts.
Abstract:
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
Abstract:
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.